Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 6/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13620001 | 0.87 | KMT2A (0.40) | CCR3TSHRKMT2AMEN1POLB | |
| SCHEMBL1411818 | 0.86 | MAPT (0.41) | CCR3TSHRKMT2AMEN1POLB | |
| SCHEMBL8988043 | 0.86 | MAPT (0.43) | CCR3KMT2AMEN1POLBMAPT | |
| SCHEMBL8989797 | 0.84 | CCR3 (0.43) | CCR3HTR2AKMT2AMEN1POLB | |
| SCHEMBL13625896 | 0.84 | CCR3 (0.41) | CCR3HTR2AKMT2AMEN1POLB | |
| SCHEMBL11995852 | 0.84 | EPHX1 (0.48) | CCR3KMT2AMEN1POLBMAPT | |
| SCHEMBL1411686 | 0.84 | EPHX1 (0.48) | CCR3KMT2AMEN1POLBMAPT | |
| SCHEMBL1411780 | 0.84 | KDM1A (0.41) | HTR2APOLBMAPTMCHR1 | |
| SCHEMBL2392413 | 0.83 | EPHX1 (0.53) | CCR3KMT2AMAPTMCHR1 | |
| SCHEMBL13619983 | 0.83 | CCR3 (0.43) | CCR3HTR2AKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281322-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281322-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281322-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDS | GOT1, GOT2, NDUFA7 | CCR3 2652/4885HTR2A 544/4885TSHR 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.